Foghorn Therapeutics Inc. FHTX 深 滬
等待開盤 09-11 09:30:00 美东时间
5.15
-0.280
-5.16%
華盛通- 最 高5.56
- 今 開5.42
- 成交量 9.71万股
- 最 低 5.1001
- 昨 收 5.43
- 總市值 2.87亿
- 52周最高 10.17
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 2.9448
- 委 比 -64.49%
- 總股本 5574.14万
- 歷史最高 28.265
- 量 比 1.35
- 振 幅 8.47%
- 歷史最低 2.70
- 每 手 1
- 風險率 1.59%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Foghorn Therapeutics Advances in Precision Therapeutics
An announcement from Foghorn Therapeutics ( ($FHTX) ) is now available. In Sept...
09-03 04:38
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
Foghorn Therapeutics Inc., a biotech company developing medicines to correct abnormal gene expression, announced that its management will participate in three key healthcare conferences in September 2025. These include Citi's Biopharma Back to School Summit on September 3, the Wells Fargo Healthcare Conference on September 4, and Morgan Stanley's Global Healthcare Conference on September 8. The company, focused on oncology through its Gene Traffi...
08-27 11:00
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers FibroGen (NASDAQ:FGEN) shares rose 20.1% to $10.11 during Monday's aft...
08-12 05:06
Ajit Singh Appointed CEO of Harbinger Health and CEO-Partner of Flagship Pioneering
Stephen Hahn to Transition to CEO Emeritus and Special Advisor and remain on Harbinger's board CAMBRIDGE, Mass., Aug. 11, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation...
08-12 00:00
Foghorn Therapeutics Q2 EPS $(0.28) Beats $(0.33) Estimate, Sales $7.557M Beat $6.498M Estimate
Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.33) by 13.85 percent. This is a 37.78 percent increase over losses of $(0.45) per share
08-05 19:37
Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update
Foghorn Therapeutics reported progress on its pipeline targeting cancers with SMARCA4 mutations, including FHD-909's ongoing Phase 1 trial in NSCLC. Preclinical data shows synergy between FHD-909 and pembrolizumab or KRAS inhibitors. The company's CBP degrader is on track for IND in 2026, while EP300 and ARID1B degraders are advancing with updates expected in Q4 2025. With a strong financial position of $198.7 million as of June 30, 2025, Foghorn...
08-05 11:00
Foghorn Therapeutics Signs New Lease Agreement
The latest update is out from Foghorn Therapeutics ( ($FHTX) ). On June 27, 202...
07-02 04:58
美股大行评级 | 潜在涨幅1281.22%！Cabaletta Bio获Guggenheim升目标价至25美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130057143861719040.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持Cabaletta Bio(CABA)"买入"评级，目标价从23美元升至25美元</p> <p>• 瑞穗：维持Tectonic Therapeutic(TECX)"跑赢大市"评级，目标价从51美元
05-16 08:43
JMP Securities Reiterates Market Outperform on Foghorn Therapeutics, Maintains $9 Price Target
JMP Securities analyst Silvan Tuerkcan reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Market Outperform and maintains $9 price target.
05-15 21:48
Foghorn Therapeutics Q1 EPS $(0.30) Beats $(0.31) Estimate, Sales $5.95M Beat $5.82M Estimate
Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.31) by 3.23 percent. This is a 49.15 percent increase over losses of $(0.59) per share
05-14 19:10
